MétaCan
Menu
Back to cohort

1435 Therapeutic mRNA cancer vaccine for GBM reaches complete response in a preclinical model

2024· article· en· W4404065577 on OpenAlexaff
Natalia Martin Orozco, Robert Nechanitzky, Shannon Snelling, Xueqing Lun, Joanna Pyczek, Kirsten Olsen, Yu Wu, Yury Karpov, Jun Liu, Matthew Gold, Haritha Menon, Yi Lin, Rajesh Krishnan, Pamela S. Ohashi, Jennifer A. Chan

Bibliographic record

VenueRegular and Young Investigator Award Abstracts · 2024
Typearticle
Languageen
FieldImmunology and Microbiology
TopicImmunotherapy and Immune Responses
Canadian institutionsPrincess Margaret Cancer CentreUniversity of CalgaryProvidence Health Care
Fundersnot available
KeywordsCancerCancer vaccineCancer researchMessenger RNAMedicineInternal medicineBiologyImmunotherapyGeneGenetics

Abstract

fetched live from OpenAlex

<h3>Background</h3> Glioblastoma (GBM) is a fatal cancer that has limited response to chemotherapy and radiotherapy. Immunotherapy for GBM has been challenging due to low frequency of neoantigens and immunosuppressive tumor microenvironment. Here we report the efficacy of a novel EGFRvIII mRNA vaccine formulated in next generation lipid nanoparticles (LNP). EGFRvIII is a cancer-driver mutation detected in approximately 30% of GBM patients, it appears as an in-frame epidermal growth factor receptor (EGFR) deletion generating a constitutively active oncogenic protein therefore considered a neoantigen driver mutation. <h3>Methods</h3> A GBM implantable cell line was generated from C3H/HeJ mice by <i>in vivo</i> electroporation to introduce genetic alterations of EGFRvIII-OE, CDKN2A-KO and PTEN-KO into periventricular cells of early postnatal mice. Resulting tumors were propagated in vitro to create cell lines. Following orthotopic implantation in 6-week-old C3H/He mice resulted in syngeneic tumors that recapitulate histologic features of GBM and caused mortality of mice by day 30. Using this GBM model, mice were intramuscularly vaccinated with either formulation buffer (fb) or EGFRv-III mRNA-LNP on day 7or 10 post tumor implantation. Four more immunizations were done before MR imaging. Mice were monitored until day 150. Brains were fixed for histological evaluation and immuno-histochemistry to determine lymphocytes, macrophages and tumor cells. T cells from spleen, and lymph nodes were analyzed to determine KLRG1, IL-7R, PD1, Ly108, CD44 and CD62L populations by flow. Anti-EGFRvIII abs were determined by ELISA. In situ spatial profiling with 10x Xenium was done in tissues for a panel of immunological markers. <h3>Results</h3> Vaccinated mice cleared tumors with no detection by histology or MRI and stayed tumor free until day 150. In contrast, control mice were diseased by day 36. Moreover, surviving vaccinated mice re-challenged on day 42 with the tumor cells, controlled the tumor with no evidence of tumor growth until day 150. The vaccination regimen induced specific EGFRvIII T cells, high numbers of Ly108+ T cells and high amounts of anti EGFRvIII antibodies. T cells are detected in brain tissue of vaccinated mice. LNP mechanism of action involved in the tumor control will be discussed. <h3>Conclusions</h3> An mRNA vaccine encoding a driver mutation in a new LNP induce an immune response that clears tumors in 100% of mice with a high-grade glioma. The vaccine induced strong T cell and antibody responses involved in controlling tumor progression. These new LNP will help progress the development of cancer vaccines for solid tumors and difficult to treat cancers.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.602
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.058
GPT teacher head0.321
Teacher spread0.263 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueRegular and Young Investigator Award AbstractsSame topicImmunotherapy and Immune ResponsesFrench-language works237,207